Document:

EX-10.10

 Exhibit 10.10 

*** Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the
Securities and Exchange Commission. 
 CONFIDENTIAL 

LICENSE AND DISTRIBUTION AGREEMENT 

THIS LICENSE AND DISTRIBUTION AGREEMENT (the
“Agreement”) is effective as of October 30, 2012 (the “Effective Date”) by and between BIOMET BIOLOGICS, LLC, a corporation organized and existing under the laws of the
State of Indiana, having a place of business at 56 East Bell Drive, Warsaw, Indiana 46582 (“Biomet”) and BIOCARDIA, INC., a Delaware corporation with its principal place of
business at 125 Shoreway Road, Suite B, San Carlos, CA 94070 (“BioCardia”). BioCardia and Biomet may be referred to individually as a “Party” or collectively as the “Parties.” 

WITNESSETH: 
 WHEREAS, Biomet
owns and controls rights in and to its proprietary product currently marketed by Biomet as the MarrowStimTM device; 

WHEREAS, BioCardia wishes to obtain from Biomet and Biomet wishes to grant to BioCardia rights to Distribute (as defined below) the Product
(as defined below) for certain applications , all on the terms and conditions set forth below. 
 NOW, THEREFORE, for good and valuable
consideration, the sufficiency and receipt of which are hereby acknowledged, the Parties hereby agree as follows: 
 1. Definitions.
As used in this Agreement, the terms defined below when capitalized shall have the following meanings: 
 1.1
“Affiliate” or “Affiliates” means, with respect to a Party, any corporation, limited liability company or other business entity controlling, controlled by or under common control with such Party, for so long as such
relationship exists. For the purposes of this definition, control means: (a) to possess, directly or indirectly, the power to direct affirmatively the management and policies of such corporation, limited liability company or other business
entity, whether through ownership of voting securities, by contract or otherwise; or (b) ownership of more than fifty percent (50%) of the voting stock in such corporation, limited liability company or other business entity (or such lesser
percent as may be the maximum that may be owned pursuant to Applicable Laws of the country of incorporation or domicile, as applicable). 

1.2 “Applicable Laws” means all laws, ordinances, rules and regulations of any governmental entity or
Regulatory Authority that apply to the Parties’ activities contemplated under this Agreement. 
 1.3
“Distribute” means to sell, distribute, market, promote, solicit orders for and provide services in connection with the Product in the Field. “Distributed” and “Distribution” have correlative
meanings. 

 CONFIDENTIAL 

 

 1.4 “Field” means preparation and use of mononuclear cells
(MNC) for intramyocardial injection of mononuclear cells (MNC). 
 1.5 “GMPs” means current good
manufacturing practices, as provided for (and as amended from time to time) in the Quality System Regulation promulgated by the FDA under the United States Food, Drug and Cosmetic Act (21 C.F.R. Part 820 et seq.) and similar requirements of
other Regulatory Authorities in the Territory, and subject to any arrangements, additions or clarifications, and the respective roles and responsibilities, agreed from time to time between the Parties. 

1.6 “Know-How” means any and all information and materials comprising (i) ideas, discoveries, inventions,
or improvements, (ii) research and development data, such as medicinal chemistry data, preclinical data, pharmacology data, chemistry data (including analytical, product characterization, manufacturing, and stability data), toxicology data,
clinical data (including investigator reports (both preliminary and final), statistical analyses, expert opinions and reports, safety and other electronic databases), analytical and quality control data and stability data, in each case together with
supporting data, (iii) databases, practices, methods, techniques, specifications, formulations, formulae, knowledge, (iv) techniques, processes, manufacturing information, and (iv) research materials, reagents and compositions of
matter. 
 1.7 “Licensed Know-How” means all Know-How owned or controlled by Biomet or its Affiliates during
the Term (as defined below) and is necessary for the Distribution, marketing and/or manufacturing of the Product in the Field within the Territory. 

1.8 “Licensed Patents” means the patent applications and patents owned or controlled by Biomet or its
Affiliates during the Term (as defined below) claiming Licensed Know-How that are listed in Exhibit 1.8 as attached hereto and (a) any patent applications claiming priority to or common priority therewith or based on the foregoing,
including all converted provisional or regular utility filings, divisionals, continuations, continuations-in-part and substitutions thereof; (b) all patents issuing on any of the foregoing, and all reissues, reexaminations, renewals and
extensions thereof; and (c) all counterparts to the foregoing in other countries. Exhibit 1.8 will be updated upon mutual agreement of the Parties to reflect changes thereto during the Term upon the addition of any patent applications or
patents to this definition. 
 1.9 “Marketing Authorization” means approval of an MAA by the applicable
Regulatory Authority. 
 1.10 “Marketing Authorization Application” or “MAA” means an
application filed with any Regulatory Authority to obtain permission to commence marketing of the Product in the Field within the Territory. 

1.11 “MarrowStimTM Technology” means the Licensed Patents and Licensed Know-How. 

  
 2 

 CONFIDENTIAL 

 

 1.12 “Milestone” means each of the diligence milestones set
forth in Exhibit 1.12 attached hereto. “Milestone 1”, “Milestone 2” and “Milestone 3” each mean the corresponding milestone event described in Exhibit 1.12. 

1.13 “Net Sales” means the amount actually received for the sale of Products by BioCardia or its Affiliates to
Third Parties less: (i) rebates, credits and cash, trade and quantity discounts, actually taken, (ii) excise taxes, sales, use, value added and other consumption taxes, and other compulsory payments to governmental authorities,
(iii) the cost of shipping the Product (iv) import and/or export duties and tariffs actually paid, and (v) amounts allowed or credited due to returns or uncollectable amounts. For clarity, Net Sales shall not include sales by
BioCardia to its Affiliates for resale, provided that if BioCardia sells Licensed Product to an Affiliate for resale, Net Sales shall include the amounts invoiced by such Affiliate to Third Parties on the resale of such Licensed Product. 

1.14 “Product” means the product described in Exhibit 1.14 as modified from time to time by agreement of the
Parties. 
 1.15 “Regulatory Authority” means, with respect to a particular country or other regulatory
jurisdiction, the regulatory agency, department, bureau or other governmental entity involved in regulating any aspect of the conduct, development, manufacture, market approval, sale, distribution, packaging or use of the Products. 

1.16 “Territory” means worldwide. 

1.17 “Third Party” means any person or entity other than the Parties and their respective Affiliates. 

1.18 “Valid Claim” shall mean a claim of an issued, unexpired patent that has not been revoked or held
unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, and that has not been
disclaimed or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 
 2. Supply of
Product. 
 2.1 General. Subject to the terms and conditions of this Agreement, Biomet shall sell to BioCardia at
the Transfer Price (as defined below) such quantities of the Product as may be specified in purchase orders submitted by BioCardia to Biomet pursuant to Section 2.2 below from time to time during the Term. For clarity, prior to BioCardia’s
achievement of Milestone 2 and the granting of exclusive Distribution rights pursuant to Section 3.1, such supply shall be for BioCardia’s own use of the Product in the Field and Territory. After achievement of Milestone 2 and the granting
of exclusive Distribution right pursuant to Section 3.1, BioCardia may continue to purchase the Product from Biomet at the Transfer Price pursuant to this Agreement for its own use in accordance with Section 4.1, in addition to purchasing
the Product for Distribution in the Field and Territory. 

  
 3 

 CONFIDENTIAL 

 

 2.2 Orders. BioCardia’s orders for the Product shall be made
pursuant to written purchase orders that specify the quantity of the Product, destination(s), and delivery date. Biomet shall acknowledge receipt and acceptance of each such purchase order (by mail, e-mail or facsimile) within ten (10) business
days from receipt of the order. In the event that BioCardia receives no response from Biomet regarding a purchase order within the ten (10) business day period, the purchase order shall be deemed to have been accepted by Biomet. No terms
contained in any purchase order, order acknowledgment, invoice or similar standardized form or correspondence shall be construed to amend or modify the terms of this Agreement, and in the event of any conflict, this Agreement shall control unless
otherwise expressly agreed by the Parties in writing. 
 2.3 Conformance / Records. 

2.3.1 Biomet shall manufacture, package, label, and ship the Product in accordance with Applicable Laws and Biomet’s specifications for
the Product. Without limiting the foregoing, Biomet agrees that, prior to each shipment of the Product hereunder, it shall perform quality control procedures reasonably necessary to ensure that the Product is free from defects. Each shipment of
Product shall conform to Applicable Law and Biomet’s specifications therefor. Biomet shall notify BioCardia of any changes to such specifications. 

2.3.2 Biomet shall generate and maintain complete and accurate records and samples as necessary to evidence compliance with this Agreement
(including without limitation Section 2.3.1) and all Applicable Laws, and other requirements of applicable Regulatory Authorities relating to the manufacture, packaging, labeling, shipping and quality control of Product. All such books, records
and samples shall be maintained during the Term of this Agreement and for two (2) years thereafter, or for such longer periods as may be required by Applicable Law and shall, during such period, be made available to BioCardia for inspection
upon BioCardia’s reasonable request upon not less than thirty (30) days prior notice by BioCardia and not more than once per calendar year. 

2.4 Delivery. Biomet shall make deliveries of the Product to the delivery destination(s) specified in the applicable
purchase order. Unless otherwise specified by BioCardia, all shipments of the Product shall be FCA (Incoterms 2010) Biomet’s manufacturing site. Biomet shall ship the Product, together with all relevant documentation relating to the Product, in
accordance with this Agreement . BioCardia shall be obligated to pay only for quantities of Product actually delivered in compliance with the applicable purchase order and the terms of this Agreement. The Product supplied by Biomet hereunder shall
be packaged according to Applicable Laws. The Product supplied hereunder shall have a minimum of two (2) years of shelf life remaining upon delivery to BioCardia. 

2.5 Acceptance/Rejection of Product.  

2.5.1 BioCardia and/or its designee shall have a period of thirty (30) days from the date of BioCardia’s receipt of each shipment of
the Product to inspect such shipment of the Product to determine whether such shipment conforms to the warranties given by Biomet in Section 9.3 

  
 4 

 *** Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 CONFIDENTIAL 
  

 
(collectively, the “Product Warranties”). If BioCardia, its Affiliates or designee, as applicable, determines that the Product does not conform to the Product Warranties, it
shall notify Biomet. 
 2.5.2 BioCardia, its Affiliate or designee, as applicable, shall have the further right to reject, at any time after
the expiration of such thirty (30)-day period, the Product on the grounds that all or part of the shipment fails to conform to the Product Warranties by providing notice thereof to Biomet; in each case, to the extent such non-conformance could not
have reasonably been discovered or determined by a visual inspection during the thirty (30)-day period. 
 2.5.3 If Biomet does not agree
with BioCardia’s determination that Product fails to conform to the Product Warranties, Biomet shall respond in writing to a rejection notice from BioCardia (or its Affiliate or designee, as applicable) within fifteen (15) calendar days
from the date of receipt of such rejection notice. In the event Biomet and BioCardia are unable to resolve such disagreement within thirty (30) calendar days of the date of the applicable rejection notice, either Party may submit a sample of
the allegedly non-conforming Product for tests and a determination as to whether or not such Product conforms to the Product Warranties to an independent laboratory mutually agreed upon by the Parties (the “Laboratory”). The
determination of the Laboratory with respect to all or part of any shipment of Product shall be final and binding upon the Parties. The fees and expenses of the Laboratory making such determination shall be borne by the Party in error with respect
to whether such Product conforms to the Product Warranties. 
 2.5.4 In the event any delivered Product is not in compliance with the
Product Warranties, such Product shall be returned to Biomet or destroyed, at Biomet’s expense. Biomet shall, at BioCardia’s election, either (i) promptly replace such non-conforming Product at no additional cost to BioCardia or
(ii) reimburse BioCardia the full amount paid by BioCardia for such non-conforming Product. 
 2.6 Failure to
Supply. In the event that Biomet fails to supply at least [***] percent ([***]%) of the quantities of the Product that BioCardia orders in any calendar quarter in accordance with the terms and conditions of this Agreement (hereinafter referred
to as a “Failure to Supply”), then subject to its royalty obligation under Section 6.2, BioCardia shall have the right, at its election, to exercise the manufacturing license granted under Section 3.1.1(b) and upon
BioCardia’s request, Biomet shall promptly transfer to BioCardia or its designee Manufacturing Know-How (as defined below) in accordance with Section 2.7. For clarity, upon the occurrence of a Failure to Supply, BioCardia shall no longer
have the obligation to meet any annual minimum purchase requirement under Milestone 3. 
 2.7 Transfer of Manufacturing
Know-How. In the event of a Failure to Supply or termination by BioCardia pursuant to Section 11.2.1, upon BioCardia’s request, (a) Biomet shall promptly make available to BioCardia or its designee access to all Licensed Know-How
owned or controlled by Biomet and its Affiliates that are necessary for the manufacturing of the Product or any of its components (collectively, “Manufacturing Know-How”); (b) Biomet shall provide advice and consultation to
BioCardia or its designee to enable BioCardia or its designee to manufacture the Product without charge to BioCardia; provided that BioCardia shall reimburse 

  
 5 

 CONFIDENTIAL 

 

 
Biomet for reasonable out-of-pocket expenses incurred by Biomet in connection with such advice and consultation. In the event that BioCardia changes manufacturers as a result of the transfer of
Manufacturing Know-How in this Section 2.7, BioCardia agrees that it assumes all responsibilities for securing regulatory clearance/approval as applicable in all countries. 

2.8 Packaging and Labeling. As between the Parties, BioCardia shall have the sole right at its own expense to determine
the trademark, trade dress, packaging specifications, labeling and the like with respect to the Product Distributed in the Field and Territory; provided that BioCardia shall mark (or caused to be marked) each Product sold hereunder with appropriate
Licensed Patent numbers and manufacturing attributions, each in accordance with Applicable Laws in the country where such Product is sold. Subject to the foregoing, the Parties shall work together in good faith to select trade dress, packaging
specifications and labeling for the Product to be Distributed in the Field in the Territory that distinguish such Product from Products intended for distribution outside of the Field. The Parties agree that the packaging and labeling specifics in
this Section 2.8 shall be addressed in the future Quality Agreement as described in Section 4.6 of this Agreement. 

2.9 Customer Support. BioCardia shall provide all support on the Product to its customers of the Product; provided that
Biomet shall use reasonable efforts to provide technical support to BioCardia if BioCardia is unable to resolve a technical or scientific issue with respect to the Product. 

2.10 Equipment Purchase. BioCardia may purchase the equipment (e.g. centrifuge and buckets) that are used in connection
with the Product as listed in Exhibit 2.10 (collectively, “Equipment”) from Biomet at Biomet’s cost. 
 3.
Exclusive Rights. 
 3.1 Grant of Distribution Rights. Effective upon BioCardia’s achievement of Milestone
2 and subject to the terms and conditions of this Agreement, Biomet hereby grants to BioCardia, and BioCardia hereby accepts, an exclusive (even as to Biomet), nontransferable (except in connection with the assignment of this Agreement in accordance
with Section 12.4) right to Distribute the Product in the Field within the Territory. Such Distribution right shall include the right to appoint and use subdistributors for the Product. 

3.1.1 Grant of Technology Licenses. Effective upon BioCardia’s achievement of Milestone 2 and subject to the terms and conditions
of this Agreement, Biomet hereby grants to BioCardia, and BioCardia hereby accepts: 
 (a) an exclusive (even as to Biomet), nontransferable
(except in connection with the assignment of this Agreement in accordance with Section 12.4), royalty-free license, including the right to grant and authorize sublicenses, under the Licensed Patents and Licensed Know-How to use, research, offer
to sell, sell, import, export and otherwise commercialize Product within the Field and Territory; 

  
 6 

 CONFIDENTIAL 

 

 (b) in the event of a Supply Failure by Biomet or termination of this Agreement by BioCardia
for cause pursuant to Section 11.2.1 and upon the express request of BioCardia, Biomet hereby grants to BioCardia an exclusive (even as to Biomet), nontransferable (except in connection with the assignment of this Agreement in accordance with
Section 12.4), royalty-free license, including the right to grant and authorize sublicenses, under the Licensed Patents and Licensed Know-How to make and have made the Product solely for commercialization within the Field and Territory; 

(c) BioCardia shall have the right to exercise the licenses granted under this Section 3.1.1 through its Affiliates, provided that
BioCardia shall be responsible for the failure by its Affiliates to comply with the terms of this Agreement including all relevant restrictions, limitations and obligations; and 

3.1.2 Grant of Trademark Licenses. Effective upon BioCardia’s achievement of Milestone 2 and subject to the terms and conditions
of this Agreement, Biomet hereby grants to BioCardia, and BioCardia hereby accepts: 
 (a) a limited, non-exclusive, nontransferable (except
in connection with the assignment of this Agreement in accordance with Section 12.4) license, including the right to grant and authorize sublicenses solely to its subdistributors of the Products, to use Biomet’s trademarks listed under
Exhibit 3.1.2 attached hereto (collectively, “Biomet Trademarks”) in connection solely with the Distribution of the Product within the Field and Territory. Biomet Trademarks shall at all times remain the exclusive property of Biomet
and all use of Biomet Trademarks shall inure to the exclusive benefit of Biomet. BioCardia shall comply with all reasonable guidelines, if any, communicated by Biomet with respect to its use of Biomet Trademarks. Prior to any use of any of the
Biomet Trademarks, BioCardia shall submit to Biomet for review and approval an example of how BioCardia proposes to use such Biomet Trademark. Once approved by Biomet, BioCardia shall not change the manner in which the Biomet Trademark is used
without the prior approval of Biomet. In the event BioCardia elects to exercise the manufacturing license granted in Section 3.1.1(b) and to use any of the Biomet Trademarks on or in connection with the Product manufactured by or for BioCardia,
the quality of the Products and BioCardia’s or the Third Party’s manufacturing facility shall comply with Biomet’s reasonable standards as they are set and amended from time to time; provided that such standards are provided to
BioCardia in writing (and identified as such) as part of the Manufacturing Know-How transferred to BioCardia pursuant to Section 2.7. Biomet may, upon not less than thirty (30) days prior notice to BioCardia and not more than once per
calendar year, inspect the manufacturing facilities used to make the Product to confirm that the facility meets such Biomet standards. BioCardia shall submit to Biomet a sample of the Product before it is Distributed for review and approval by
Biomet. Once approved, BioCardia shall not change the Product without the prior approval of Biomet. 
 3.2 Data.
During the term of this Agreement, BioCardia shall have the exclusive (other than to Biomet) right to develop and publish data with respect to the Product in the Field and Territory (collectively, “Data”) in accordance with the laws
and regulations within the countries of interest; provided that BioCardia shall provide Biomet with a written copy of any 

  
 7 

 CONFIDENTIAL 

 

 
proposed publication or other disclosure of the Data at least ninety (90) days prior to submission for publication or disclosure for Biomet’s review and approval, which approval shall
not be unreasonably withheld. If Biomet rejects the publication or disclosure within such ninety (90) day review period then BioCardia will not publish or otherwise publicly distribute the publication or disclosure to any third party. In the
event Biomet fails to notify BioCardia of its approval or rejection of such publication within such ninety (90) day review period, BioCardia shall be free to proceed with the proposed publication or disclosure. For clarity, it is understood
that Biomet may continue to develop and publish data with respect to the use of the Product outside the Field. 
 4. Regulatory
Matters. 
 4.1 Marketing Authorization. In the event that Biomet elects not to obtain or maintain any regulatory
license, approval, authorization or clearance necessary for the marketing and sale of the Product in the Field as an equipment platform in the Territory, BioCardia shall have the right to obtain the same. BioCardia shall have the exclusive right to
generate preclinical data, conduct clinical trials and obtain Marketing Authorization for the use of mononuclear cells generated using the Product in the Field. For clarity, BioCardia shall have the exclusive right to seek, obtain and maintain
Marketing Authorizations that are necessary or useful for the marketing and sale of the Product for specific therapeutic indications within the Field in the Territory. BioCardia will keep Biomet reasonably informed with respect to the status of the
application, grant or maintenance of any such Marketing Authorization and Biomet agrees to reasonably cooperate with BioCardia with respect thereto, including by transferring Licensed Know-How necessary or useful for such purposes as requested by
BioCardia pursuant to Section 4.2. 
 4.2 Transfer of Licensed Know-How. Upon BioCardia’s request, Biomet
shall deliver (and shall cause its personnel to deliver) to BioCardia, all Licensed Know-How that is necessary or useful for BioCardia to prepare and submit MAAs for the Product in accordance with Section 4.1 and to otherwise exercise its
rights and fulfill its obligations under this Agreement. Biomet shall provide BioCardia with reasonable access, at agreed times during ordinary business hours, to Biomet personnel knowledgeable of the research giving rise to the Licensed Patents or
Licensed Know-How to enable BioCardia to use or practice the Licensed Patents and Licensed Know-How. 
 4.3 Permits.
Except as otherwise provided in Section 4.1, each Party, at its own cost, shall be responsible for obtaining all permits, registrations, licenses, exemptions, exceptions and other permissions that are necessary for its performance of its
obligations under this Agreement. 
 4.4 Adverse Event Reporting. Each Party will promptly notify the other of any
deaths, serious injuries, or other adverse events related to the Product, and any other complaints related to the Product, of which such first Party becomes aware. Each Party shall cooperate with the other Party and provide information in its
possession to the extent necessary for the other Party to comply with its obligations under Applicable Law relating to the manufacture, marketing 

  
 8 

 *** Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 CONFIDENTIAL 
  

 
or Distribution of the Product in the Field and Territory in accordance with this Agreement. The Parties agree that the adverse event reporting specifics and responsibilities in this
Section 4.4 shall be addressed in the future Quality Agreement as described in Section 4.6 of this Agreement. 

4.5 Recalls. Each of BioCardia and Biomet will immediately inform the other in writing if it believes one or more lots
of the Product should be subject to recall from Distribution, withdrawal or other field action. To the extent permitted by Applicable Law and public safety, the Parties will confer before initiating any recall or other field action, provided that
BioCardia shall have the final decision-making authority as to any such recall, withdrawal or field action concerning the Product in the Field with respect to which BioCardia holds a Marketing Authorization. Otherwise Biomet shall have the final
decision-making authority with respect to any such recall, withdrawal or field action. BioCardia shall be responsible to maintain distribution records for all Products and to execute the recall communication and retrieval for all concerned Product.
The Party initiating the recall shall initially bear the cost thereof and shall carry out the recall in accordance with best industry practices. In the event it is determined that a recall resulted from a breach by either Party of any of its
representations, warranties, duties or obligations under this Agreement, such Party shall be responsible for the costs of the recall; provided that if both Parties share responsibility with respect to such recall, the costs shall be shared in the
ratio of the Parties’ contributory responsibility. The Parties shall each maintain traceability records as are sufficient and as may be necessary to permit a recall. 

4.6 The Parties agree to complete a Quality Agreement after the Effective Date of this Agreement. Such Quality Agreement,
addressing concerns including but not limited to Quality, Regulatory, Compliance and other matters related to Biomet providing the Product, shall be agreed to prior to the first sale of the Product. 

5. Diligence Obligations of BioCardia. 

5.1 Diligence Obligations. BioCardia shall be obligated to achieve each Milestone within the corresponding timeline as
set forth in Exhibit 1.12. In the event this Agreement is assigned pursuant to Section 12.4 to a Third Party successor that is (a) a public company with a market capitalization equal to or greater than [***] U.S. Dollars ($[***]),
or (b) a company with annual sales equal to or greater than [***] U.S. Dollars ($[***]) (each of (a) and (b), a “Qualified Acquirer”), the annual minimum purchase requirement under Milestone 3 shall be adjusted as
specified in Exhibit 1.12. 
 5.2 Extension of Milestone. 

5.2.1 In the event BioCardia is unable to achieve any Milestone for any reason other than as specified in Section 2.6, BioCardia will
have the right and option to extend the timeline of such Milestone and all subsequent Milestone(s) for up to three (3) years by making extension payment(s) as follows: 
  

	 	•	 	$[***] for the first year extension 

  
 9 

 *** Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 CONFIDENTIAL 
  

	 	•	 	$[***] for the second year extension 

  

	 	•	 	$[***] for the third year extension 

 Additional extensions may be granted only by mutual written agreement of
both Parties. 
 5.2.2 Without limiting Sections 5.2.1, in the event BioCardia fails to order the annual minimum purchase amount required
under Milestone 3 for any given year, BioCardia shall have the right to make up the shortfall by paying Biomet the amount equal to the Transfer Price multiplied by the number of additional units that BioCardia is required to order in order to meet
the applicable annual minimum purchase amount. 
 5.3 Biomet’s Right to Terminate this Agreement. Subject to
BioCardia’s right to extend the timeline for any Milestone and the right to make up the shortfall for any minimum purchase requirement as set forth in Section 5.2, Biomet has the right to terminate this Agreement pursuant to
Section 11.2.1(a) in the event BioCardia fails to meet any Milestone. For clarity, any failure to meet a Milestone that is a result of Biomet’s failure to supply Products in accordance with BioCardia’s purchase orders shall not be
deemed a failure or breach by BioCardia for purposes of this Agreement, including this Section 5.3. 
 6. Payment Terms. 

6.1 Transfer Prices. The prices for the Product sold by Biomet to BioCardia during the Term shall be as set forth on the
Exhibit 6.1 attached to this Agreement (the “Transfer Prices”). In the event this Agreement is assigned by BioCardia to a Qualified Acquirer pursuant to Section 12.4, the Transfer Prices shall be adjusted as set forth in
Exhibit 6.1. 
 6.2 Royalty. In the event that BioCardia exercises its manufacturing license under
Section 3.1.1(b), BioCardia shall pay Biomet a royalty in the amount of [***] percent ([***]%) of Net Sales of the Products that are manufactured and sold by or on behalf of BioCardia or its Affiliate pursuant to its exercise of such license.

 6.3 Royalty Reports and Payments. During the period during which BioCardia is obligated to pay a royalty to Biomet
under Section 6.2, BioCardia shall provide a royalty report to Biomet, within forty five (45) days after the end of each calendar quarter, showing: (i) the aggregate Net Sales of the Product for such calendar quarter; and (ii) a
calculation of total royalties due to Biomet under Section 6.2. Simultaneously with the delivery of each such report, BioCardia shall pay to Biomet the total royalties, if any, due to Biomet in accordance with Section 6.2 for the period of
such report. Such reports shall be deemed to be the Confidential Information of BioCardia, even if not marked as confidential. 

6.4 Payment Method. All payments under this Agreement shall be made by bank wire transfer in immediately available funds
to an account designated by the Party to which such payments are due. All payments under this Agreement shall be paid in United States Dollars. If any currency conversion shall be required in connection with the calculation of

  
 10 

 CONFIDENTIAL 

 

 
amounts payable hereunder, such conversion shall be made using the same exchange rates used by BioCardia for its own financial reporting purposes, or if none is used, then the average of the
buying and selling rates on the day such payment is made as published by The Wall Street Journal, Internet Edition at www.wsj.com. 

6.5 Withholdings. Any and all withholding or similar taxes imposed or levied on account of the payment of amounts under
this Agreement, which are required to be withheld, shall be deducted by the payer prior to remittance and shall be paid to the proper taxing authority. Proof of payment shall be secured, if available, and sent to the payee as evidence of such
payment in such form as required by the tax authorities having jurisdiction over the payer. Each Party agrees to cooperate with the other Party in claiming exemptions from such deductions or withholdings under any agreement or treaty from time to
time in effect. 
 7. Intellectual Property. 

7.1 Patent Prosecution. As between the Parties, Biomet will retain the first right and responsibility to prosecute and
maintain the Licensed Patents in the Field in the Territory. Biomet shall keep BioCardia reasonably informed as to the status of the Licensed Patents and shall consult with BioCardia in a timely manner concerning (i) the scope and content of
patent applications within the Licensed Patents prior to filing such patent applications, and (ii) the content of and proposed responses to official actions of the United States Patent and Trademark Office and foreign patent offices during
prosecution of such patent applications. In the event Biomet decides to abandon any patent within the Licensed Patent, BioCardia shall have the right to undertake prosecution and maintenance of such Licensed Patent at its expense. Upon
BioCardia’s request, Biomet shall file patent applications within the Licensed Patents in any jurisdiction(s) requested by BioCardia, provided that BioCardia shall reimburse Biomet for the reasonable, documented, out-of-pocket expenses incurred
by Biomet for such additional patent filings. Except as expressly provided herein, Biomet shall bear all the costs incurred in connection with the filing, prosecution and maintenance of all Licensed Patents. 

7.2 Enforcement. In the event that either Party reasonably believes that any Licensed Patent is being infringed by a
Third Party or is subject to a declaratory judgment action arising from such infringement, in each case within the Field and Territory, such Party shall promptly notify the other Party. In such event, Biomet shall have the initial right (but not the
obligation) to enforce such Licensed Patents with respect to such infringement in the Field, or to defend any declaratory judgment action with respect thereto (an “Enforcement Action”), at Biomet’s expense. In the event that
Biomet fails to initiate an Enforcement Action to enforce such Licensed Patent against an infringement in the Field in the Territory within ninety (90) days of a request by BioCardia to do so, BioCardia may initiate an Enforcement Action
against such infringement at its own expense. The Party initiating or defending any such Enforcement Action (the “Enforcing Party”) shall keep the other Party reasonably informed of the progress of any such Enforcement Action, and
such other Party shall have the right to participate with counsel of its own choice at its own expense. In any event, the other Party shall reasonably cooperate with the Enforcing Party, including providing information and materials, at the
Enforcing Party’s 

  
 11 

 *** Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 CONFIDENTIAL 
  

 
request and expense. BioCardia shall not enter into any consent judgment or other voluntary final disposition of any Infringement Action within the Field and Territory without the prior written
consent of Biomet, , which consent shall not be unreasonably conditioned, withheld or delayed. Any recovery received as a result of any Enforcement Action to enforce Licensed Patents pursuant to this Section 7.2 shall be used first to reimburse
the Parties for the costs and expenses (including attorneys’ and professional fees) incurred in connection with such Enforcement Action (and not previously reimbursed), and the remainder of the recovery shall be shared [***] percent ([***]%) to
the Enforcing Party and [***] percent ([***]%) to the other Party. Neither Party shall enter into any settlement of any claim described in this Section 7.2 that adversely affects the other Party’s rights or interests without such other
Party’s written consent, which consent shall not be unreasonably conditioned, withheld or delayed. 
 8. Confidential
Information. 
 8.1 Confidential Information. During the term of this Agreement and for five (5) years
thereafter, except as provided herein, each Party shall maintain in confidence, and shall not use for any purpose or disclose to any Third Party except as provided below, information that is disclosed by the other Party in writing and marked
“Confidential” or that is disclosed orally and confirmed in writing as confidential within forty-five (45) days following such disclosure, or that is otherwise reasonably expected to be treated in a confidential manner based on the
circumstances of its disclosure and the nature of the information (collectively, “Confidential Information”). Confidential Information shall not include any information that can be established by the receiving Party: (i) was
already known to the receiving Party at the time of disclosure hereunder, (ii) now or hereafter becomes publicly known other than through acts or omissions of the receiving Party, (iii) was disclosed to the receiving Party by a Third Party
under no obligation of confidentiality to the disclosing Party, or (iv) was independently developed by the receiving Party without use of or reference to the Confidential Information of the disclosing Party as shown by the receiving
Party’s then-contemporaneous written records. 
 8.2 Permitted Usage. Each Party may use Confidential Information
of the other Party for purposes of exercising its rights and performing its obligations under this Agreement. Each Party may disclose Confidential Information of the other Party as follows: (i) under appropriate confidentiality provisions
substantially equivalent to those in this Agreement, in connection with the performance of its obligations or exercise of rights under this Agreement; (ii) to the extent such disclosure is reasonably necessary in filing for, obtaining and
maintaining regulatory approvals, or otherwise required by Applicable Law, provided, however, that if a Party is required by law to make any such disclosure of the other Party’s Confidential Information it will, to the extent legally
permissible and practicable, give reasonable advance notice to the other Party of such disclosure requirement and, except to the extent inappropriate in the case of patent applications, will use its reasonable efforts to secure confidential
treatment of such Confidential Information required to be disclosed; (iii) in communication with existing and potential investors, partners, acquirers, collaborators, licensees, advisors (including consultants, financial advisors, attorneys and
accountants) and others on a need to know basis, in each case under appropriate 

  
 12 

 CONFIDENTIAL 

 

 
confidentiality provisions substantially equivalent to those of this Agreement; or (iv) to the extent mutually agreed to by the Parties. 

8.3 Prior Agreements. This Agreement supersedes the Mutual Confidentiality Agreement between the Parties dated
May 10, 2012 (the “Prior Agreement”) with respect to information disclosed thereunder. All information exchanged between the Parties under the Prior Agreement shall be deemed Confidential Information of the disclosing Party and
shall be subject to the terms of this Article 8. 
 8.4 Confidential Terms. Each Party agrees not to disclose to any
Third Party the terms and conditions of this Agreement without the prior approval of the other Party, except to advisors (including consultants, financial advisors, attorneys and accountants), potential and existing investors, partners, acquirers,
collaborators, contractors and others on a need to know basis, in each case under circumstances that reasonably protect the confidentiality thereof, or to the extent necessary to comply with the terms of agreements with Third Parties, or to the
extent required by applicable law, including securities laws and rules of any recognized stock exchange. Each Party may issue press releases relating to this Agreement or activities conducted hereunder, provided that such Party shall submit the text
of such press releases to the other Party for its approval prior to the issuance thereof, such approval not to be unreasonably withheld, conditioned or delayed. After BioCardia’s achievement of Milestone 2, the Parties will work together in
good faith to issue a joint press release regarding the Agreement upon the request of either Party. For clarity, either Party may issue press releases related to this Agreement or the activities conducted hereunder to the extent the content of such
press releases was previously approved, or included in a press release made, by the other Party. 
 9. Representations and
Warranties. 
 9.1 Due Organization, Valid Existence and Due Authorization. Each Party hereto represents and
warrants to the other Party as follows: (a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation; (b) it has full corporate power and authority and has taken all corporate action necessary to enter
into and perform this Agreement; (c) the execution and performance by it of its obligations hereunder will not constitute a breach of, or conflict with, its organizational documents nor any other agreement, court order, consent decree or other
arrangement, whether written or oral, by which it is bound; and (d) this Agreement is its legal, valid and binding obligation, enforceable against such Party in accordance with the terms and conditions hereof. 

9.2 Representations, Warranties and Covenants of Biomet. Biomet hereby further represents, warrants and covenants to
BioCardia that: 
 9.2.1 It has the right to grant the rights granted to BioCardia herein, and Biomet and its Affiliates have not, and shall
not, grant any rights (including any lien or security interest) that conflict with such rights or that would otherwise prevent BioCardia from exercising its rights or performing its obligations hereunder; 

  
 13 

 CONFIDENTIAL 

 

 9.2.2 Neither Biomet nor any of its employees or permitted subcontractors performing or
involved with the development or commercialization of the Product or its performance under this Agreement have been “debarred” by the FDA or a regulatory authority in any jurisdiction outside the U.S., nor have debarment proceedings
against Biomet or any of its employees or permitted subcontractors been commenced; 
 9.2.3 There are no threatened or pending actions,
suits, investigations, claims or proceedings in any way relating to the Licensed Patents or Licensed Know-How; 
 9.2.4 Biomet is the sole
owner or licensee of the patents and patent applications listed on Exhibit 1.8 and does not, as of the Effective Date, own or control any patents or patent applications that would dominate the practice of the patents and patent applications listed
on Exhibit 1.8 in accordance with this Agreement. 
 9.3 Product Warranties. Biomet represents and warrants that: 

9.3.1 Biomet’s manufacturing facility and the Product supplied hereunder shall comply with this Agreement and all Applicable Laws
(including GMPs). The Product sold to BioCardia hereunder shall be free from defects in material and workmanship and shall conform to Biomet’s specifications therefor. Biomet shall perform and document all manufacturing and supply activities
contemplated herein in compliance with all Applicable Laws (including GMPs). 
 9.3.2 Title to the Product sold to BioCardia by Biomet under
this Agreement shall be free and clear of any security interest, lien, or other encumbrance. 
 9.3.3 To the best of Biomet’s
knowledge, the manufacture and sale of the Product by BioCardia hereunder will not infringe or misappropriate any intellectual property right of any Third Party. 

9.4 Representations, Warranties and Covenants of BioCardia. 

9.4.1 Neither BioCardia nor any of its employees or permitted subcontractors who will be involved in the Distribution, marketing, sale, use or
manufacture of the Product or its performance under this Agreement have been “debarred” by the FDA or a regulatory authority in any jurisdiction outside the U.S., nor have debarment proceedings against BioCardia or any of its employees or
permitted subcontractors been commenced; 
 9.4.2 BioCardia’s manufacturing facility complies with this Agreement and all Applicable
Laws (including GMP’s). Any Product manufactured by BioCardia or by a Third Party (other than Biomet) for BioCardia shall be free from defects in material and workmanship and shall conform to the specifications therefor. BioCardia shall perform
and document all manufacturing and supply activities contemplated on the manufacture of the Product by BioCardia in compliance with all applicable laws (including GMP’s). 

  
 14 

 CONFIDENTIAL 

 

 9.5 Disclaimer. EACH PARTY AGREES AND ACKNOWLEDGES THAT, EXCEPT AS
EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND WHATSOEVER, IMPLIED OR STATUTORY, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, IMPLIED OR STATUTORY, INCLUDING
WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AGAINST NON-INFRINGEMENT OR THE LIKE, OR ARISING FROM COURSE OF PERFORMANCE. 

9.6 Limitation of Liability. EXCEPT FOR EITHER PARTY’S INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 10 OR BREACH OF
CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 8, TO THE EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, COST OF
PROCUREMENT OF SUBSTITUTE GOODS, OR ANY INDIRECT DAMAGES EVEN IF SUCH PARTY HAS BEEN INFORMED OF THE POSSIBILITY THEREOF. 
 10.
Indemnity. 
 10.1 By Biomet. Subject to Section 10.3, Biomet shall indemnify, defend and hold harmless
BioCardia, its Affiliates and their respective directors, officers, representatives and employees (each, an “BioCardia Indemnitee”) from and against any and all liabilities, damages or expenses (including reasonable legal expenses
and attorneys’ fees) (collectively, “Losses”) resulting from any suit, claim, action or demand brought by a Third Party (each, a “Third Party Claim”) arising out of: (a) any material breach of any of
Biomet’s representations, warranties, obligations or covenants under this Agreement; or (b) the gross negligence or willful misconduct of a Biomet Indemnitee. Biomet’s obligation to indemnify the BioCardia Indemnitees pursuant to this
Section 10.1 shall not apply to the extent that any such Losses are Losses that BioCardia is obligated to indemnify the Biomet Indemnitees pursuant to Section 10.2 below. 

10.2 By BioCardia. Subject to Section 10.3, BioCardia shall indemnify, defend or settle and hold harmless Biomet,
its Affiliates and their respective directors, officers, representatives and employees (each, a “Biomet Indemnitee”) from and against any and all Losses resulting from any Third Party Claim arising out of: (a) any material
breach of any of BioCardia’s representations, warranties, obligations or covenants under this Agreement; or (c) the gross negligence or willful misconduct of a BioCardia Indemnitee. BioCardia’s obligation to indemnify the Biomet
Indemnitees pursuant to this Section 10.2 shall not apply to the extent that any such Losses are Losses that Biomet is obligated to indemnify the BioCardia Indemnitees pursuant to Section 10.1 above. 

10.3 Indemnification Procedure. To be eligible to be indemnified hereunder, the indemnified Party shall provide the
indemnifying Party with prompt notice of the Third-Party Claim giving rise to the indemnification obligation pursuant to this Article 10 and the right to 

  
 15 

 CONFIDENTIAL 

 

 
control the defense (with the reasonable cooperation of the indemnified Party) and settlement of any such claim; provided, however, that the indemnifying Party shall not enter into any settlement
that admits fault, wrongdoing or damages without the indemnified Party’s written consent, such consent not to be unreasonably withheld or delayed. The indemnified Party shall have the right to participate, at its own expense and with counsel of
its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party; provided that the indemnifying Party shall have no obligations with respect to any Losses resulting from the indemnified Party’s admission,
settlement or other communication without the prior written consent of the indemnifying Party. 
 11. Term and Termination. 

11.1 Term. The term of this Agreement shall commence on the Effective Date and shall continue in full force and effect
until the later of (a) ten (10) years after the Effective Date, or (b) expiration of the last-to-expire Valid Claim within the Licensed Patents (the “Term”). 

11.2 Termination. 

11.2.1 Termination for Cause. Either Party may terminate this Agreement prior to its expiration and upon thirty (30) days prior
written notice if: 
 (a) the other Party breaches any material term (including any payment terms) of this Agreement and the breaching Party
has not cured the breach within such thirty (30) day period, provided, however, if the Party alleged to be in breach disputes in good faith such breach by written notice to the other Party within such thirty (30) day period, then the
non-breaching Party shall not have the right to terminate this Agreement unless and until it has been determined that this Agreement was materially breached pursuant to Section 12.6 and the breaching Party fails to cure such breach within
thirty (30) days after such determination; or 
 (b) the other Party is the subject of a liquidation or insolvency, or the filing of
bankruptcy, or similar proceeding(s) (provided that in the case of involuntary proceedings, such proceedings are not dismissed within sixty (60) days of filing). 

11.2.2 Termination by BioCardia. BioCardia shall have the right to terminate this Agreement if, in its sole discretion, the safety,
efficacy, or comparative effectiveness of the Product in the Field is insufficient to meet BioCardia’s commercial needs, by providing Biomet with ninety (90) days’ prior written notice. 

11.3 Effect of Termination. 

11.3.1 In the event this Agreement is terminated by BioCardia pursuant to Section 11.2.1, the licenses granted under Section 3.1.1
(including the manufacturing license granted under Section 3.1.1(b)) shall survive until the later of (a) ten (10) years after the Effective Date, or (b) expiration of the last-to-expire Valid Claim within the Licensed Patents.
Upon such termination, at BioCardia’s request, Biomet shall promptly transfer to BioCardia the Manufacturing Know-How in 

  
 16 

 *** Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
 CONFIDENTIAL 
  

 
accordance with Section 4.2. In the event this Agreement is terminated by BioCardia pursuant to Section 11.2.1(b) then BioCardia’s royalty obligations under Section 6.2 shall
survive. In the event this Agreement is terminated by BioCardia pursuant to Section 11.2.1(a) then BioCardia’s royalty obligations under Section 6.2 shall terminate. 

11.3.2 Without limiting Section 11.3.1, upon expiration or termination of this Agreement for any reason, BioCardia shall have [***]
months following the expiration or termination of this Agreement to continue to Distribute within the Field any Product held by BioCardia as of the effective date of expiration or termination. 

11.3.3 In the event this Agreement is terminated by Biomet pursuant to Section 11.2.1(a) or 11.2.1(b), Biomet shall have a first right of
negotiation to complete any ongoing clinical studies of the mononuclear cells generated using the Product that were initiated by BioCardia prior to such termination, to seek Marketing Authorization for BioCardia’s delivery system for use with
mononuclear cells generated using the Product in the Field and to commercialize such BioCardia delivery system for such use in the Field; provided that if the Parties do not reach agreement with respect to the terms and conditions of such rights
within ninety (90) days after such a termination, BioCardia shall have no further obligation under this Section 11.3.3. 
 11.3.4
Each Party shall, within thirty (30) days of the effective date of termination or expiration, either (a) return to the other Party all of the other Party’s Confidential Information then in a Party’s possession or control or
(b) certify to the other Party in writing that all copies of such Confidential Information have been destroyed. 
 11.3.5 Expiration or
termination of this Agreement for any reason shall not release either Party hereto from any obligation (including payment obligations) or liability which, at the time of such expiration or termination, has already accrued to the other Party or which
is attributable to a period prior to such expiration or termination, nor preclude either Party from pursuing all rights or remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. 

11.3.6 The provisions of Articles 1, 8, 10 and 12 and Sections 2.5, 9.5, 9.6 and 11.3 shall survive termination or expiration of this
Agreement. All other provisions of this Agreement shall terminate upon any termination or expiration of this Agreement. 
 12.
Miscellaneous. 
 12.1 Events Beyond Control. Neither Party shall be liable for any failure to fulfill any term
or condition of this Agreement (other than the obligation to pay) if fulfillment has been delayed, hindered or prevented by an event of force majeure including, but not limited to, any strike, lockout or other industrial dispute, acts of the
elements, compliance with requirements of any governmental port or international authority, plant breakdown or failure of equipment, inability to obtain equipment, fuel, power, materials or transportation, or by any circumstances whatsoever beyond
its reasonable control (“Force Majeure Event”). A Party affected by a Force Majeure Event will promptly notify the other Party, explaining the nature and expected duration thereof and such Party shall use all reasonable efforts to
remedy or mitigate such Force Majeure 

  
 17 

 CONFIDENTIAL 

 

 
Event and the effects thereof. Notwithstanding the foregoing, if a Party is unable to perform any of its obligations under this Agreement for a period of more than ninety (90) days as a
result of a Force Majeure Event, the other Party may terminate this Agreement upon written notice to the affected Party. 

12.2 Independent Contractors. The relationship of the Parties established by this Agreement is that of independent
contractors, and nothing contained in this Agreement shall be construed to create any other relationship between the Parties. Neither Party shall have any right, power, or authority to assume, create or incur any expense, liability, or obligation,
express or implied, on behalf of the other. 
 12.3 Notice. All notices issued or served under this Agreement shall be
in writing and shall be deemed to have been sufficiently given if transmitted by facsimile (receipt verified), email (receipt verified) or by express courier service (signature required) or seven (7) days after it was sent by registered letter.
All notices shall be sent to the following, except as otherwise specified by either Party in writing: 
  

							
	To Biomet:		To BioCardia:
	Attn:		Legal Department				
	Biomet Biologics, LLC		BioCardia, Inc.
			 56 East Bell Drive
 Warsaw, Indiana
46582
				 125 Shoreway Road, Suite B
 San Carlos,
California 94070

 12.4 Assignment. This Agreement shall not be assignable by either Party to any Third
Party without the written consent of the other Party and any such attempted assignment shall be void. Notwithstanding the foregoing, either Party may assign this Agreement, without the written consent of the other Party, to its Affiliate or an
entity that acquires all or substantially all of the business or assets of such Party to which this Agreement pertains (whether by merger, reorganization, acquisition, sale or otherwise), and agrees in writing to be bound by the terms and conditions
of this Agreement. No assignment or transfer of this Agreement shall be valid and effective unless and until the assignee/transferee agrees in writing to be bound by the provisions of this Agreement. The terms and conditions of this Agreement shall
be binding on and inure to the benefit of the permitted successors and assigns of the Parties. Except as expressly provided in this Section 12.4, any attempted assignment or transfer of this Agreement shall be null and void. 

12.5 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of
Delaware without regard to the conflicts of laws provisions. 
 12.6 Dispute Resolution. In the event of any dispute,
controversy or claim between the parties hereto arising out of this Agreement, the parties agree to attempt to resolve such dispute in good faith through direct negotiations for a period of thirty (30) days. Unless

  
 18 

 CONFIDENTIAL 

 

 
otherwise provided in this Agreement, any dispute, controversy or claim between the parties hereto arising out of or relating to this Agreement which cannot be resolved through direct
negotiations shall be settled by binding arbitration in accordance with and subject to the then applicable rules (“Rules”) of the Judicial Arbitration and Mediation Services (“JAMS”) and such arbitration shall be
administered by JAMS with a single arbitrator selected from a list of arbitrators proposed by JAMS in accordance with the Rules. The arbitrator shall allow such discovery as is appropriate and consistent with the purposes of arbitration in
accomplishing fair, speedy and cost-effective resolution of disputes. The costs of the arbitration including the arbitrators’ fees shall be shared equally by the parties. Judgment upon the award rendered in any such arbitration may be entered
in any court of competent jurisdiction, or application may be made to such court for a judicial acceptance of the award and an order of enforcement, as the law of such jurisdiction may require or allow. Unless otherwise mutually agreed to by the
parties, such arbitration shall take place in Denver, Colorado. 
 12.7 Waiver; Amendment. The failure of either party
to enforce its rights under this Agreement at any time for any period shall not be construed as a waiver of such rights unless evidenced in writing and signed for on behalf of both parties. Any modification or amendment of, or addition to, the terms
of this Agreement shall not be effective unless in a writing conspicuously entitled “Amendment of Agreement” which begins with a proposal to amend this Agreement and specifies exactly each change to be made and which is signed by an
authorized officer of both parties. 
 12.8 Severability. If any provision of this Agreement is held to be void,
invalid or unenforceable, the same shall be reformed to give the fullest effect to the intention of the parties when executing this Agreement while complying with Applicable Law or stricken if not so conformable, so as not to affect the validity or
enforceability of the remainder of this Agreement. 
 12.9 Headings. Headings herein are for convenience of reference
only and shall in no way affect interpretation of this Agreement. 
 12.10 Entire Agreement. This Agreement, together
with the exhibits attached hereto, constitute the entire understanding and contract between the parties and supersedes any and all prior and contemporaneous, oral or written representations, communications, understandings, and agreements between the
parties with respect to the subject matter hereof. Notwithstanding the foregoing, to the extent the terms and conditions of this Agreement conflict with the terms and conditions of any exhibit, the terms and conditions of this Agreement shall
govern. The parties acknowledge and agree that neither of the parties is entering into this Agreement on the basis of any representations or promises not expressly contained herein. 

THE TERMS AND CONDITIONS OF THIS AGREEMENT ARE AGREED TO AND ACCEPTED BY: 

 

					
	BIOCARDIA, INC.				BIOMET BIOLOGICS, LLC

									
					
	Name:		 Peter Altman
				Name:		 Joel Higgins

					
	Title:		 CEO
				Title:		 Vice President and General Manager

					
	Signature:		 /s/ Peter Altman
				Signature:		 /s/ Joel Higgins

					
	Date:		 October 30, 2012
				Date:		 October 30, 2012

  
 19 

 *** Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 EXHIBIT 1.8 

LICENSED PATENTS 
  

			
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]
		
	[***]		[***]

 *** Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 EXHIBIT 1.12 

DILIGENCE MILESTONES 

Milestone 1 Within [***] after the Effective Date, BioCardia shall publish or present at a national conference data to validate that
MNC produced using MarrowstimTM Technology has utility for the Field. 
 Milestone 2
Within [***] after the Effective Date, BioCardia shall complete enrollment of no less than ten (10) patients in the first human clinical study on the use of the Product in the Field for support of the filing of Marketing Authorization with
FDA, subject to review and approval of the location and protocol synopsis of the study by Biomet, not to be unreasonably withheld, delayed or conditioned. 

Milestone 3 Annual minimum purchase requirements beginning [***] years from the Effective Date of this Agreement. 

 

					
	 Year (i.e. each [***] period starting from the [***]
anniversary of the Effective Date)
	  	 Marrowstim Kit (Product) Units
	  	 Marrowstim Kit (Product) Units
  

(In the event this Agreement is assigned by
BioCardia to a Qualified Acquirer)

			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]
			
	[***]	  	[***]	  	[***]

 EXHIBIT 1.14 

DESCRIPTION OF PRODUCT 
 The
“Product” will always include either the 60ml MarrowstimTM Tube or the 30ml MarrowstimTM Tube. Current configurations of the “Product” are outlined below. 

 

					
	 Description
	  	 Catalog Number

	MarrowStimTM Standard Kit with ACD-A	  	800-0613A
		 	 Contents:
 One Disposable 60ml
MarrowstimTM Tube
 One 10ml Syringe
 Four 30ml Syringes

One 18 Gauge Centesis Needle
 One 18 Gauge Safety Apheresis
Needle
 One 30ml Bottle of ACD-A
 One Bone Marrow Aspiration
Needle
 One Adhesive Tape 54 Inch
 Two 2x2 Gauze

Four Syringe Tips
	  	
	Provides 6ml of output from 60 ml of input.	  	
	MarrowStimTM Mini Kit with ACD-A	  	800-0612A
		 	 Contents:
 One Disposable 30ml Mini
MarrowstimTM Tube
 One 10ml Syringe
 Three 30ml
Syringes
 One 18 Gauge Centesis Needle
 One 18 Gauge Safety
Apheresis Needle
 One 30ml Bottle of ACD-A
 One Bone Marrow
Aspiration Needle
 One Adhesive Tape 54 Inch
 Two 2x2 Gauze

Four Syringe Tips
	  	
	Provides 3ml of output from 30ml of input.	  	
	MarrowStimTM Standard Tube Only (no kit accessories)	  	800-0622
	MarrowStimTM Mini Tube Only (no kit accessories)	  	800-0623

 *** Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 EXHIBIT 2.10 

EQUIPMENT AND EQUIPMENT SUPPLIERS 
  

			
	 Description
	  	 Catalog Number

		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]

 EXHIBIT 3.1.2 

BIOMET TRADEMARKS 
 Biomet® 

Biomet Biologics 
 MarrowStim 

 *** Confidential material redacted and filed separately with the Securities and Exchange
Commission. 
  

 EXHIBIT 6.1 

TRANSFER PRICE 
 MarrowStimTM device (device only without accessories included in the Kit): 
 $[***]/unit or [***]%
([***]% in the event this Agreement is assigned by BioCardia to a Qualified Acquirer) of BioCardia’s Average Selling Price (ASP) within the applicable country where such MarrowStimTM device
is being sold, whichever is higher. 
 MarrowStimTM Concentration Kit (including MarrowStimTM device and BMA needle, syringes and other components of the MarrowStimTM Concentration Kit as currently marketed by Biomet) 

$[***]/unit or [***]% ([***]% in the event this Agreement is assigned by BioCardia to a Qualified Acquirer) of BioCardia’s ASP within the
applicable country where such MarrowStimTM Concentration Kit is being sold, whichever is higher.EX-10.11

 Exhibit 10.11 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER
THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION
REQUIREMENTS OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE, TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY
APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, TRANSFER, PLEDGE OR HYPOTHECATION OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED HEREBY. 

WARRANT TO PURCHASE SHARES OF SERIES F PREFERRED STOCK 

of 
 BIOCARDIA, INC.

 Dated as of «Date» 

Void after the date specified in Section 8 
  

			
	No. «Warrant_No»		 Warrant to Purchase

«No_of_Shares» Shares of

Series F Preferred Stock

(subject to adjustment)

 THIS CERTIFIES THAT, for value received, «Warrant_Holder», or its registered assigns (the
“Holder”), is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from BioCardia, Inc., a Delaware corporation (the “Company”), shares of the
Company’s Series F Preferred Stock, $0.001 par value per share (the “Shares”), in the amounts, at such times and at the price per share set forth in Section 1. The term “Warrant” as used
herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. This Warrant is issued in connection with the transactions described in the Series F Preferred Stock and Warrant Purchase
Agreement, dated as of April 24, 2013, by and among the Company and the purchasers described therein (the “Purchase Agreement”). The holder of this Warrant is subject to certain restrictions set forth in the Purchase
Agreement and the Investor Rights Agreement, dated as of June 6, 2011, by and among the Company and the other parties named therein (together with the Purchase Agreement, the “Series F Transaction Documents”). This
Warrant is one of a series of warrants referred to as the “Series F Warrants” in the Purchase Agreement. 
 The
following is a statement of the rights of the Holder and the conditions to which this Warrant is subject, and to which Holder, by acceptance of this Warrant, agrees: 

1. Number and Price of Shares; Exercise Period. 

(a) Number of Shares. Subject to any previous exercise of the Warrant, the Holder shall have the right to purchase up to
«No_of_Shares» Shares, as may be adjusted pursuant hereto, prior to (or in connection with) the expiration of this Warrant as provided in Section 8. 

 (b) Exercise Price. The exercise price per Share shall be equal to $1.75, subject
to adjustment pursuant hereto (the “Exercise Price”). 
 (c) Exercise Period. This Warrant shall be
exercisable, in whole or in part, prior to (or in connection with) the expiration of this Warrant as set forth in Section 8. 
 2.
Exercise of the Warrant. 
 (a) Exercise. The purchase rights represented by this Warrant may be exercised at the election
of the Holder, in whole or in part, in accordance with Section 1, by: 
 (i) the tender to the Company at its principal office (or
such other office or agency as the Company may designate) of a notice of exercise in the form of Exhibit A (the “Notice of Exercise”), duly completed and executed by or on behalf of the Holder, together with the
surrender of this Warrant; and 
 (ii) the payment to the Company of an amount equal to (x) the Exercise Price multiplied by
(y) the number of Shares being purchased, by (a) wire transfer or certified, cashier’s or other check acceptable to the Company and payable to the order of the Company; (b) surrender and cancellation of promissory notes or other
instruments representing indebtedness of the Company to the Holder; or (c) a combination of (a) and (b). 
 (b) Net Issue
Exercise. In lieu of exercising this Warrant pursuant to Section 2(a)(ii), if the fair market value of one Share is greater than the Exercise Price (at the date of calculation as set forth below), the Holder may elect to receive a
number of Shares equal to the value of this Warrant (or of any portion of this Warrant being canceled) by surrender of this Warrant at the principal office of the Company (or such other office or agency as the Company may designate) together with a
properly completed and executed Notice of Exercise reflecting such election, in which event the Company shall issue to the Holder that number of Shares computed using the following formula: 

 

							
	 X
  
		     =    

 
		        Y (A – B)        		
	 	 	  
	  	
			A		

 Where: 
  

					
	X		=		The number of Shares to be issued to the Holder
			
	Y		=		The number of Shares purchasable under this Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being canceled (at the date of such calculation)
			
	A		=		The fair market value of one Share (at the date of such calculation)
			
	B		=		The Exercise Price (as adjusted to the date of such calculation)

  
 - 2 - 

 For purposes of the calculation above, the fair market value of one Share shall be determined by
the Board of Directors of the Company, acting in good faith; provided, however, that: 
 (i) where a public market exists for the
Company’s common stock at the time of such exercise, the fair market value per Share shall be the product of (x) the average of the closing bid prices of the common stock or the closing price quoted on the national securities exchange on
which the common stock is listed as published in the Wall Street Journal, as applicable, for the ten (10) trading day period ending five (5) trading days prior to the date of determination of fair market value and (y) the
number of shares of common stock into which each Share is convertible at the time of such exercise, as applicable; and 
 (ii) if the
Warrant is exercised in connection with the Company’s initial public offering of common stock, the fair market value per Share shall be the product of (x) the per share offering price to the public of the Company’s initial public
offering and (y) the number of shares of common stock into which each Share is convertible at the time of such exercise, as applicable. 

(c) Stock Certificates. The rights under this Warrant shall be deemed to have been exercised and the Shares issuable upon such
exercise shall be deemed to have been issued immediately prior to the close of business on the date this Warrant is exercised in accordance with its terms, and the person entitled to receive the Shares issuable upon such exercise shall be treated
for all purposes as the holder of record of such Shares as of the close of business on such date. As promptly as reasonably practicable on or after such date, the Company shall issue and deliver to the person or persons entitled to receive the same
a certificate or certificates for that number of shares issuable upon such exercise. In the event that the rights under this Warrant are exercised in part and have not expired, the Company shall execute and deliver a new Warrant reflecting the
number of Shares that remain subject to this Warrant. 
 (d) No Fractional Shares or Scrip. No fractional shares or scrip
representing fractional shares shall be issued upon the exercise of the rights under this Warrant. In lieu of such fractional share to which the Holder would otherwise be entitled, the Company shall make a cash payment equal to the Exercise Price
multiplied by such fraction. 
 (e) Conditional Exercise. The Holder may exercise this Warrant conditioned upon (and effective
immediately prior to) consummation of any transaction that would cause the expiration of this Warrant pursuant to Section 8 by so indicating in the notice of exercise. 

(f) Reservation of Stock. The Company agrees during the term the rights under this Warrant are exercisable to take all
reasonable action to reserve and keep available from its authorized and unissued shares of Series F Preferred Stock for the purpose of effecting the exercise of this Warrant such number of shares (and shares of common stock for issuance on
conversion of such shares) as shall from time to time be sufficient to effect the exercise of the rights under this Warrant; and if at any time the number of authorized but unissued shares of Series F Preferred Stock (and shares of common stock
for issuance on conversion of such shares) shall not be sufficient for purposes of the exercise of this Warrant in accordance with its terms and the conversion of the Shares, without limitation of such other remedies as may be available to the
Holder, the Company will use all reasonable efforts to take such corporate action as may, in the opinion of counsel, be necessary to increase its authorized and unissued shares of its Series F Preferred Stock (and shares of common stock for
issuance on conversion of such shares) to a number of shares as shall be sufficient for such purposes. 
 3. Replacement of the
Warrant. Subject to the receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably
satisfactory in form and substance to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant, the Company at the expense of the Holder shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor
and amount. 

  
 - 3 - 

 4. Transfer of the Warrant. 

(a) Warrant Register. The Company shall maintain a register (the “Warrant Register”) containing the name
and address of the Holder or Holders. Until this Warrant is transferred on the Warrant Register in accordance herewith, the Company may treat the Holder as shown on the Warrant Register as the absolute owner of this Warrant for all purposes,
notwithstanding any notice to the contrary. Any Holder of this Warrant (or of any portion of this Warrant) may change its address as shown on the Warrant Register by written notice to the Company requesting a change. 

(b) Warrant Agent. The Company may appoint an agent for the purpose of maintaining the Warrant Register referred to in
Section 4(a), issuing the Shares or other securities then issuable upon the exercise of the rights under this Warrant, exchanging this Warrant, replacing this Warrant or conducting related activities. 

(c) Transferability of the Warrant. Subject to the provisions of this Warrant with respect to compliance with the Securities Act
of 1933, as amended (the “Securities Act”) and limitations on assignments and transfers, including without limitation compliance with the restrictions on transfer set forth in Section 5, title to this Warrant may be
transferred by endorsement (by the transferor and the transferee executing the assignment form attached as Exhibit B (the “Assignment Form”)) and delivery in the same manner as a negotiable instrument transferable by
endorsement and delivery. 
 (d) Exchange of the Warrant upon a Transfer. On surrender of this Warrant (and a properly
endorsed Assignment Form) for exchange, subject to the provisions of this Warrant with respect to compliance with the Securities Act and limitations on assignments and transfers, the Company shall issue to or on the order of the Holder a new warrant
or warrants of like tenor, in the name of the Holder or as the Holder (on payment by the Holder of any applicable transfer taxes) may direct, for the number of shares issuable upon exercise hereof, and the Company shall register any such transfer
upon the Warrant Register. This Warrant (and the securities issuable upon exercise of the rights under this Warrant) must be surrendered to the Company or its warrant or transfer agent, as applicable, as a condition precedent to the sale, pledge,
hypothecation or other transfer of any interest in any of the securities represented hereby. 
 (e) Taxes. In no event shall
the Company be required to pay any tax which may be payable in respect of any transfer involved in the issue and delivery of any certificate in a name other than that of the Holder, and the Company shall not be required to issue or deliver any such
certificate unless and until the person or persons requesting the issue thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid or is not payable. 

5. Restrictions on Transfer of the Warrant and Shares; Compliance with Securities Laws. By acceptance of this Warrant, the Holder
agrees to comply with the following: 
 (a) Restrictions on Transfers. Any transfer of this Warrant or the Shares or the
shares of common stock issuable upon conversion of the Shares (the “Securities”) must be in compliance with all applicable federal and state securities laws. The Holder agrees not to make any sale, assignment, transfer,
pledge or other disposition of all or any portion of the Securities, or any beneficial interest therein, unless and until the transferee thereof has agreed in writing for the benefit of the Company to take and hold such Securities subject to, and to
be bound by, the terms and conditions set forth in this Warrant to the same extent as if the transferee were the original Holder hereunder, and 

  
 - 4 - 

 (i) there is then in effect a registration statement under the Securities Act covering such
proposed disposition and such disposition is made in accordance with such registration statement, or 
 (ii) (A) such Holder shall
have given prior written notice to the Company of such Holder’s intention to make such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, (B) the
transferee shall have confirmed to the satisfaction of the Company in writing, substantially in the form of Exhibit A-1, that the Securities are being acquired (i) solely for the transferee’s own account and not as a nominee for any
other party, (ii) for investment and (iii) not with a view toward distribution or resale, and shall have confirmed such other matters related thereto as may be reasonably requested by the Company, and (C) such Holder shall have
furnished the Company, at the Company’s expense, with (i) an opinion of counsel, reasonably satisfactory to the Company, to the effect that such disposition will not require registration of such Securities under the Securities Act or
(ii) a “no action” letter from the Securities and Exchange Commission to the effect that the transfer of such Securities without registration will not result in a recommendation by the staff of the Securities and Exchange Commission
that action be taken with respect thereto, whereupon such Holder shall be entitled to transfer such Securities in accordance with the terms of the notice delivered by the Holder to the Company. 

(b) Permitted Transfers. Permitted transfers include (i) a transfer not involving a change in beneficial ownership, or
(ii) transactions involving the distribution without consideration of Securities by any Holder to (x) a parent, subsidiary or other affiliate of a Holder that is a corporation, (y) any of the Holder’s partners, members or other
equity owners, or retired partners or members, or to the estate of any of its partners, members or other equity owners or retired partners or members, or (z) a venture capital fund that is controlled by or under common control with one or more
general partners or managing members of, or shares the same management company with, the Holder; provided, in each case, that the Holder shall give written notice to the Company of the Holder’s intention to effect such disposition and
shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition. 
 (c)
Investment Representation Statement. Unless the rights under this Warrant are exercised pursuant to an effective registration statement under the Securities Act that includes the Shares with respect to which the Warrant was exercised,
it shall be a condition to any exercise of the rights under this Warrant that the Holder shall have confirmed to the satisfaction of the Company in writing, substantially in the form of Exhibit A-1, that the Shares so purchased are being
acquired solely for the Holder’s own account and not as a nominee for any other party, for investment and not with a view toward distribution or resale and that the Holder shall have confirmed such other matters related thereto as may be
reasonably requested by the Company. 
 (d) Securities Law Legend. The Securities shall (unless otherwise permitted by the
provisions of this Warrant) be stamped or imprinted with a legend substantially similar to the following (in addition to any legend required by state securities laws): 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION
REQUIREMENTS OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR 

  
 - 5 - 

 
HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. THIS CERTIFICATE MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE
SALE, TRANSFER, PLEDGE OR HYPOTHECATION OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED HEREBY. 
 (e) Market Stand-off
Legend. The Shares and common stock issued upon exercise hereof or conversion thereof shall also be stamped or imprinted with a legend in substantially the following form: 

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD IN THE EVENT
OF A PUBLIC OFFERING, AS SET FORTH IN THE WARRANT PURSUANT TO WHICH THESE SHARES WERE ISSUED, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY. 

(f) Instructions Regarding Transfer Restrictions. The Holder consents to the Company making a notation on its records and giving
instructions to any transfer agent in order to implement the restrictions on transfer established in this Section 5. 
 (g)
Removal of Legend. The legend referring to federal and state securities laws identified in Section 5(d) stamped on a certificate evidencing the Shares (and the common stock issuable upon conversion thereof) and the stock transfer
instructions and record notations with respect to such securities shall be removed and the Company shall issue a certificate without such legend to the holder of such securities if (i) such securities are registered under the Securities Act, or
(ii) such holder provides the Company with an opinion of counsel reasonably acceptable to the Company to the effect that a sale or transfer of such securities may be made without registration or qualification. 

6. Adjustments. Subject to the expiration of this Warrant pursuant to Section 8, the number and kind of shares purchasable
hereunder and the Exercise Price therefor are subject to adjustment from time to time, as follows: 
 (a) Merger or
Reorganization. If at any time there shall be any reorganization, recapitalization, merger or consolidation (a “Reorganization”) involving the Company (other than as otherwise provided for herein or as would cause the
expiration of this Warrant under Section 8) in which shares of the Company’s stock are converted into or exchanged for securities, cash or other property, then, as a part of such Reorganization, lawful provision shall be made so that the
Holder shall thereafter be entitled to receive upon exercise of this Warrant, the kind and amount of securities, cash or other property of the successor corporation resulting from such Reorganization, equivalent in value to that which a holder of
the Shares deliverable upon exercise of this Warrant would have been entitled in such Reorganization if the right to purchase the Shares hereunder had been exercised immediately prior to such Reorganization. In any such case, appropriate adjustment
(as determined in good faith by the Board of Directors of the successor corporation) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder after such Reorganization to the end that
the provisions of this Warrant shall be applicable after the event, as near as reasonably may be, in relation to any shares or other securities deliverable after that event upon the exercise of this Warrant. 

(b) Reclassification of Shares. If the securities issuable upon exercise of this Warrant are changed into the same or a
different number of securities of any other class or classes by reclassification, capital reorganization, conversion of all outstanding shares of the relevant class or series (other than as would 

  
 - 6 - 

 
cause the expiration of this Warrant pursuant to Section 8) or otherwise (other than as otherwise provided for herein) (a “Reclassification”), then, in any such
event, in lieu of the number of Shares which the Holder would otherwise have been entitled to receive, the Holder shall have the right thereafter to exercise this Warrant for a number of shares of such other class or classes of stock that a holder
of the number of securities deliverable upon exercise of this Warrant immediately before that change would have been entitled to receive in such Reclassification, all subject to further adjustment as provided herein with respect to such other
shares. 
 (c) Subdivisions and Combinations. In the event that the outstanding shares of Series F Preferred Stock are
subdivided (by stock split, by payment of a stock dividend or otherwise) into a greater number of shares of such securities, the number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such subdivision shall,
concurrently with the effectiveness of such subdivision, be proportionately increased, and the Exercise Price shall be proportionately decreased, and in the event that the outstanding shares of Series F Preferred Stock are combined (by
reclassification or otherwise) into a lesser number of shares of such securities, the number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such combination shall, concurrently with the effectiveness of such
combination, be proportionately decreased, and the Exercise Price shall be proportionately increased. 
 (d) Redemption. In
the event that all of the outstanding shares of the securities issuable upon exercise of this Warrant are redeemed in accordance with the Company’s certificate of incorporation, this Warrant shall thereafter be exercisable for a number of
shares of the Company’s common stock equal to the number of shares of common stock that would have been received if this Warrant had been exercised in full immediately prior to such redemption and the preferred stock received thereupon had been
simultaneously converted into common stock. 
 (e) Notice of Adjustments. Upon any adjustment in accordance with this
Section 6, the Company shall give notice thereof to the Holder, which notice shall state the event giving rise to the adjustment, the Exercise Price as adjusted and the number of securities or other property purchasable upon the exercise of the
rights under this Warrant, setting forth in reasonable detail the method of calculation of each. The Company shall, upon the written request of any Holder, furnish or cause to be furnished to such Holder a certificate setting forth (i) such
adjustments, (ii) the Exercise Price at the time in effect and (iii) the number of securities and the amount, if any, of other property that at the time would be received upon exercise of this Warrant. 

7. Notification of Certain Events. Prior to the expiration of this Warrant pursuant to Section 8, in the event that the Company
shall authorize: 
 (a) the issuance of any dividend or other distribution on the capital stock of the Company (other than
(i) dividends or distributions otherwise provided for in Section 6, (ii) repurchases of common stock issued to or held by employees, officers, directors or consultants of the Company or its subsidiaries upon termination of their
employment or services pursuant to agreements providing for the right of said repurchase; (iii) repurchases of common stock issued to or held by employees, officers, directors or consultants of the Company or its subsidiaries pursuant to rights
of first refusal or first offer contained in agreements providing for such rights; or (iv) repurchases of capital stock of the Company in connection with the settlement of disputes with any stockholder), whether in cash, property, stock or
other securities; 
 (b) the voluntary liquidation, dissolution or winding up of the Company; or 

(c) any transaction resulting in the expiration of this Warrant pursuant to Section 8(b) or 8(c); 

  
 - 7 - 

 the Company shall send to the Holder of this Warrant at least ten (10) days prior written notice of the date
on which a record shall be taken for any such dividend or distribution specified in clause (a) or the expected effective date of any such other event specified in clause (b) or (c), as applicable. The notice provisions set forth in this
section may be shortened or waived prospectively or retrospectively by the consent of the holders of a majority of the Shares issuable upon exercise of the rights under the Series F Preferred Warrants. 

8. Expiration of the Warrant. This Warrant shall expire and shall no longer be exercisable as of the earlier of: 

(a) 5:00 p.m., Pacific time, on date that is three (3) years from the Initial Closing date as defined in the Purchase Agreement; 

(b) (i) the acquisition of the Company by another entity by means of any transaction or series of related transactions to which the Company is
a party (including, without limitation, any stock acquisition, reorganization, merger or consolidation, but excluding any sale of stock for capital raising purposes and any transaction effected primarily for purposes of changing the Company’s
jurisdiction of incorporation) other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain,
immediately after such transaction or series of transactions, as a result of shares in the Company held by such holders prior to such transaction or series of transactions, at least a majority of the total voting power represented by the outstanding
voting securities of the Company or such other surviving or resulting entity (or if the Company or such other surviving or resulting entity is a wholly-owned subsidiary immediately following such acquisition, its parent), or (ii) a sale, lease
or other disposition of all or substantially all of the assets of the Company and its subsidiaries taken as a whole by means of any transaction or series of related transactions, except where such sale, lease or other disposition is to a
wholly-owned subsidiary of the Company; or 
 (c) Immediately prior to the closing of a firm commitment underwritten initial public offering
pursuant to an effective registration statement filed under the Securities Act covering the offering and sale of the Company’s common stock. 

9. No Rights as a Stockholder. Nothing contained herein shall entitle the Holder to any rights as a stockholder of the Company or to be
deemed the holder of any securities that may at any time be issuable on the exercise of the rights hereunder for any purpose nor shall anything contained herein be construed to confer upon the Holder, as such, any right to vote for the election of
directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification of stock, change of par value or change of
stock to no par value, consolidation, merger, conveyance or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or any other rights of a stockholder of the Company until the rights under the Warrant shall have
been exercised and the Shares purchasable upon exercise of the rights hereunder shall have become deliverable as provided herein. 
 10.
Market Stand-off. The Holder of this Warrant hereby agrees that such Holder shall not sell or otherwise transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same
economic effect as a sale, of any common stock (or other securities) of the Company held by the Holder (other than those included in the registration) during the one hundred eighty (180) day period following the effective date of the
registration statement for the Company’s initial public offering filed under the Securities Act (or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (i) the publication or
other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions 

  
 - 8 - 

 
contained in NASD Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto). The obligations described in this section shall not apply to a registration
relating solely to employee benefit plans on Form S-l or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. The
Company may impose stop-transfer instructions and may stamp each certificate with a legend as substantially set forth in Section 5(e) with respect to the shares of common stock (or other securities) subject to the foregoing restriction until
the end of such one hundred eighty (180) day (or other) period. The Holder agrees to execute a market stand-off agreement with the underwriters in the offering in customary form consistent with the provisions of this section. 

11. Representations and Warranties of the Holder. By acceptance of this Warrant, the Holder represents and warrants to the Company as
follows: 
 (a) No Registration. The Holder understands that the Securities have not been, and will not be, registered under
the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the
Holder’s representations as expressed herein or otherwise made pursuant hereto. 
 (b) Investment Intent. The Holder is
acquiring the Securities for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof. The Holder has no present intention of selling, granting any participation
in, or otherwise distributing the Securities, nor does it have any contract, undertaking, agreement or arrangement for the same. 
 (c)
Investment Experience. The Holder has substantial experience in evaluating and investing in private placement transactions of securities in companies similar to the Company, and has such knowledge and experience in financial or
business matters so that it is capable of evaluating the merits and risks of its investment in the Company and protecting its own interests. 

(d) Speculative Nature of Investment. The Holder understands and acknowledges that the Company has a limited financial and
operating history and that its investment in the Company is highly speculative and involves substantial risks. The Holder can bear the economic risk of its investment and is able, without impairing its financial condition, to hold the Securities for
an indefinite period of time and to suffer a complete loss of its investment. 
 (e) Access to Data. The Holder has had an
opportunity to ask questions of officers of the Company, which questions were answered to its satisfaction. The Holder believes that it has received all the information that it considers necessary or appropriate for deciding whether to acquire the
Securities. The Holder understands that any such discussions, as well as any information issued by the Company, were intended to describe certain aspects of the Company’s business and prospects, but were not necessarily a thorough or exhaustive
description. The Holder acknowledges that any business plans prepared by the Company have been, and continue to be, subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature, and it
can be expected that some or all of the assumptions underlying the projections will not materialize or will vary significantly from actual results. 

(f) Accredited Investor. The Holder is an “accredited investor” within the meaning of Regulation D,
Rule 501(a), promulgated by the Securities and Exchange Commission and agrees to submit to the Company such further assurances of such status as may be reasonably requested by the Company. 

  
 - 9 - 

 (g) Residency. The residency of the Holder (or, in the case of a partnership or
corporation, such entity’s principal place of business) is correctly set forth on the signature page hereto. 
 (h) Restrictions
on Resales. The Holder acknowledges that the Securities must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available. The Holder is aware of the provisions of
Rule 144 promulgated under the Securities Act, which permit resale of shares purchased in a private placement subject to the satisfaction of certain conditions, which may include, among other things, the availability of certain current public
information about the Company; the resale occurring not less than a specified period after a party has purchased and paid for the security to be sold; the number of shares being sold during any three-month period not exceeding specified limitations;
the sale being effected through a “broker’s transaction,” a transaction directly with a “market maker” or a “riskless principal transaction” (as those terms are defined in the Securities Act or the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder); and the filing of a Form 144 notice, if applicable. The Holder acknowledges and understands that the Company may not be satisfying the current public
information requirement of Rule 144 at the time the Holder wishes to sell the Securities and that, in such event, the Holder may be precluded from selling the Securities under Rule 144 even if the other applicable requirements of
Rule 144 have been satisfied. The Holder acknowledges that, in the event the applicable requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration will be required for any disposition of
the Securities. The Holder understands that, although Rule 144 is not exclusive, the Securities and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities received in a private offering other than in
a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales and that such persons and the brokers who participate in the
transactions do so at their own risk. 
 (i) No Public Market. The Holder understands and acknowledges that no public market
now exists for any of the securities issued by the Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities. 

(j) Brokers and Finders. The Holder has not engaged any brokers, finders or agents in connection with the Securities, and the
Company has not incurred nor will incur, directly or indirectly, as a result of any action taken by the Holder, any liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with the Securities.

 (k) Legal Counsel. The Holder has had the opportunity to review this Warrant, the exhibits and schedules attached hereto
and the transactions contemplated by this Warrant with its own legal counsel. The Holder is not relying on any statements or representations of the Company or its agents for legal advice with respect to this investment or the transactions
contemplated by this Warrant. 
 (l) Tax Advisors. The Holder has reviewed with its own tax advisors the U.S. federal, state
and local and non-U.S. tax consequences of this investment and the transactions contemplated by this Warrant. With respect to such matters, the Holder relies solely on any such advisors and not on any statements or representations of the Company or
any of its agents, written or oral. The Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment and the transactions contemplated by this Warrant. 

12. Miscellaneous. 
 (a)
Amendments. Except as expressly provided herein, neither this Warrant nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument 

  
 - 10 - 

 
referencing this Warrant and signed by the Company and the holders of warrants representing not less than a majority of the Shares issuable upon exercise of any and all outstanding Series F
Preferred Warrants, which majority does not need to include the consent of the Holder. Any amendment, waiver, discharge or termination effected in accordance with this Section 9(a) shall be binding upon each holder of the Series F
Preferred Warrants, each future holder of such Series F Preferred Warrants and the Company; provided, however, that no special consideration or inducement may be given to any such holder in connection with such consent that is not given
ratably to all such holders, and that such amendment must apply to all such holders equally and ratably in accordance with the number of shares of Series F Preferred Stock issuable upon exercise of the Series F Preferred Warrants. The
Company shall promptly give notice to all holders of Series F Preferred Warrants of any amendment effected in accordance with this Section 9(a). 

(b) Waivers. No waiver of any single breach or default shall be deemed a waiver of any other breach or default theretofore or
thereafter occurring. 
 (c) Notices. All notices and other communications required or permitted hereunder shall be in writing
and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail (if to the Holder) or otherwise delivered by hand, messenger or courier service addressed: 

(i) if to the Holder, to the Holder at the Holder’s address, facsimile number or electronic mail address as shown in the Company’s
records, as may be updated in accordance with the provisions hereof, or until any such Holder so furnishes an address, facsimile number or electronic mail address to the Company, then to and at the address, facsimile number or electronic mail
address of the last holder of this Warrant for which the Company has contact information in its records; or 
 (ii) if to the Company, to
the attention of the President or Chief Financial Officer of the Company at the Company’s address as shown on the signature page hereto, or at such other current address as the Company shall have furnished to the Holder, with a copy (which
shall not constitute notice) to Michael Danaher, Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, CA 94304. 

Each such notice or other communication shall for all purposes of this Warrant be treated as effective or having been given (i) if
delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or
(ii) if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii) if sent via
facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during
normal business hours of the recipient, then on the recipient’s next business day. In the event of any conflict between the Company’s books and records and this Warrant or any notice delivered hereunder, the Company’s books and
records will control absent fraud or error. 
 (d) Governing Law. This Warrant and all actions arising out of or in connection
with this Warrant shall be governed by and construed in accordance with the laws of California, without regard to the conflicts of law provisions of California, or of any other state. 

(e) Jurisdiction and Venue. Each of the Holder and the Company irrevocably consents to the exclusive jurisdiction and venue of
any court within Santa Clara County, California, in connection with any matter based upon or arising out of this Warrant or the matters contemplated herein, and agrees that process may be served upon them in any manner authorized by the laws of the
California for such persons. 

  
 - 11 - 

 (f) Titles and Subtitles. The titles and subtitles used in this Warrant are used
for convenience only and are not to be considered in construing or interpreting this Warrant. All references in this Warrant to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits
attached hereto. 
 (g) Severability. If any provision of this Warrant becomes or is declared by a court of competent
jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Warrant, and such illegal, unenforceable or void provision shall be replaced with a
valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, unenforceable or void provision. The balance of this Warrant shall be enforceable in accordance with its terms.

 (h) Waiver of Jury Trial. EACH OF THE HOLDER AND THE COMPANY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY AND ALL
RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS WARRANT. If the waiver of jury trial set forth in this paragraph is not enforceable, then any claim or cause of
action arising out of or relating to this Warrant shall be settled by judicial reference pursuant to California Code of Civil Procedure Section 638 et seq. before a referee sitting without a jury, such referee to be mutually acceptable
to the parties or, if no agreement is reached, by a referee appointed by the Presiding Judge of the California Superior Court for Santa Clara County. This paragraph shall not restrict the Holder or the Company from exercising remedies under the
Uniform Commercial Code or from exercising pre-judgment remedies under applicable law. 
 (i) California Corporate Securities
Law. THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS WARRANT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE
CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102, OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS WARRANT ARE
EXPRESSLY CONDITIONED UPON THE QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT. 
 (j) Saturdays, Sundays and
Holidays. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday, Sunday or U.S. federal holiday, then such action may be taken or such right may be exercised
on the next succeeding day that is not a Saturday, Sunday or U.S. federal holiday. 
 (k) Rights and Obligations Survive Exercise of
the Warrant. Except as otherwise provided herein, the rights and obligations of the Company and the Holder under this Warrant shall survive exercise of this Warrant. 

(l) Entire Agreement. Except as expressly set forth herein, this Warrant (including the exhibits attached hereto) constitutes
the entire agreement and understanding of the Company and the Holder with respect to the subject matter hereof and supersede all prior agreements and understandings relating to the subject matter hereof. 

(signature page follows) 

  
 - 12 - 

 The Company signs this Warrant as of the date stated on the first page. 

 

			
	BIOCARDIA, INC.
		
	By:		  

		
	Name:		  

		
	Title:		  

		
	Address:		
	125 Shoreway Rd., Suite B
	San Carlos, CA 94070

 (Signature Page to Warrant to Purchase Shares of Series F Preferred Stock of
BioCardia, Inc.) 

 EXHIBIT A 

NOTICE OF EXERCISE 
  

			
	TO:		BIOCARDIA, INC. (the “Company”)
		
	Attention:		President

  

	(1)	Exercise. The undersigned elects to purchase the following pursuant to the terms of the attached warrant: 

  

			
	Number of shares:		  

		
	Type of security:		  

  

	(2)	Method of Exercise. The undersigned elects to exercise the attached warrant pursuant to: 

  

			
	 ̈		A cash payment or cancellation of indebtedness, and tenders herewith payment of the purchase price for such shares in full, together with all applicable transfer taxes, if any.
		
	 ̈		The net issue exercise provisions of Section 2(b) of the attached warrant.

  

	(3)	Conditional Exercise. Is this a conditional exercise pursuant to Section 2(e): 

  

							
	 ̈		Yes		 ̈    		No

 If “Yes,” indicate the applicable condition: 

 

	
	  

  

	(4)	Stock Certificate. Please issue a certificate or certificates representing the shares in the name of: 

  

					
	 ̈		The undersigned		
			
	 ̈		Other—Name:		  

			
			        Address:		  

			
					  

  

	(5)	Unexercised Portion of the Warrant. Please issue a new warrant for the unexercised portion of the attached warrant in the name of: 

 

					
	 ̈		The undersigned		
			
	 ̈		Other—Name:		  

			
			        Address:		  

			
					  

			
	 ̈		Not applicable		

  
 A-1 

	(6)	Investment Intent. The undersigned represents and warrants that the aforesaid shares are being acquired for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in
connection with, the distribution thereof, and that the undersigned has no present intention of selling, granting any participation in, or otherwise distributing the shares, nor does it have any contract, undertaking, agreement or arrangement for
the same, and all representations and warranties of the undersigned set forth in Section 11 of the attached warrant are true and correct as of the date hereof. 

 

	(7)	Investment Representation Statement and Market Stand-Off Agreement. The undersigned has executed, and delivers herewith, an Investment Representation Statement and Market Stand-Off Agreement in a form
substantially similar to the form attached to the warrant as Exhibit A-1. 

  

	(8)	Consent to Receipt of Electronic Notice. Subject to the limitations set forth in Delaware General Corporation Law §232(e), the undersigned consents to the delivery of any notice to stockholders given by the
Company under the Delaware General Corporation Law or the Company’s certificate of incorporation or bylaws by (i) facsimile telecommunication to the facsimile number provided below (or to any other facsimile number for the undersigned in
the Company’s records), (ii) electronic mail to the electronic mail address provided below (or to any other electronic mail address for the undersigned in the Company’s records), (iii) posting on an electronic network together
with separate notice to the undersigned of such specific posting or (iv) any other form of electronic transmission (as defined in the Delaware General Corporation Law) directed to the undersigned. This consent may be revoked by the undersigned
by written notice to the Company and may be deemed revoked in the circumstances specified in Delaware General Corporation Law §232. 

  

	
	  

	(Print name of the warrant holder)
	
	  

	(Signature)
	
	  

	(Name and title of signatory, if applicable)
	
	  

	(Date)
	
	  

	(Fax number)
	
	  

	(Email address)

 (Signature page to the Notice of Exercise) 

  
 A-2 

 EXHIBIT A-l 

INVESTMENT REPRESENTATION STATEMENT 

AND 
 MARKET STAND-OFF
AGREEMENT 
  

					
	INVESTOR:		«WARRANT_HOLDER»
		
	COMPANY:		BIOCARDIA, INC.
		
	SECURITIES:		THE WARRANT ISSUED ON «DATE» (THE “WARRANT”) AND THE SECURITIES ISSUED OR ISSUABLE UPON EXERCISE THEREOF (INCLUDING UPON SUBSEQUENT CONVERSION OF THOSE SECURITIES)
			
	DATE:		  
		

 In connection with the purchase or acquisition of the above-listed Securities, the undersigned Investor
represents and warrants to, and agrees with, the Company as follows: 
 1. No Registration. The Investor understands that the
Securities have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration provisions of the Securities Act, the
availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Investor’s representations as expressed herein or otherwise made pursuant hereto. 

2. Investment Intent. The Investor is acquiring the Securities for investment for its own account, not as a nominee or agent, and not
with a view to, or for resale in connection with, any distribution thereof. The Investor has no present intention of selling, granting any participation in, or otherwise distributing the Securities, nor does it have any contract, undertaking,
agreement or arrangement for the same. 
 3. Investment Experience. The Investor has substantial experience in evaluating and
investing in private placement transactions of securities in companies similar to the Company, and has such knowledge and experience in financial or business matters so that it is capable of evaluating the merits and risks of its investment in the
Company and protecting its own interests. 
 4. Speculative Nature of Investment. The Investor understands and acknowledges that the
Company has a limited financial and operating history and that its investment in the Company is highly speculative and involves substantial risks. The Investor can bear the economic risk of its investment and is able, without impairing its financial
condition, to hold the Securities for an indefinite period of time and to suffer a complete loss of its investment. 
 5. Access to
Data. The Investor has had an opportunity to ask questions of officers of the Company, which questions were answered to its satisfaction. The Investor believes that it has received all the information that it considers necessary or appropriate
for deciding whether to acquire the Securities. The Investor understands that any such discussions, as well as any information issued by the Company, were intended to describe certain aspects of the Company’s business and prospects, but were
not necessarily a 

  
 A-1-1 

 
thorough or exhaustive description. The Investor acknowledges that any business plans prepared by the Company have been, and continue to be, subject to change and that any projections included in
such business plans or otherwise are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the projections will not materialize or will vary significantly from actual results. 

6. Accredited Investor. The Investor is an “accredited investor” within the meaning of Regulation D, Rule 501(a),
promulgated by the Securities and Exchange Commission and agrees to submit to the Company such further assurances of such status as may be reasonably requested by the Company. 

7. Residency. The residency of the Investor (or, in the case of a partnership or corporation, such entity’s principal place of
business) is correctly set forth on the signature page hereto. 
 8. Restrictions on Resales. The Investor acknowledges that the
Securities must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available. The Investor is aware of the provisions of Rule 144 promulgated under the Securities Act, which
permit resale of shares purchased in a private placement subject to the satisfaction of certain conditions, which may include, among other things, the availability of certain current public information about the Company; the resale occurring not
less than a specified period after a party has purchased and paid for the security to be sold; the number of shares being sold during any three-month period not exceeding specified limitations; the sale being effected through a “broker’s
transaction,” a transaction directly with a “market maker” or a “riskless principal transaction” (as those terms are defined in the Securities Act or the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder); and the filing of a Form 144 notice, if applicable. The Investor acknowledges and understands that the Company may not be satisfying the current public information requirement of Rule 144 at the time the
Investor wishes to sell the Securities and that, in such event, the Investor may be precluded from selling the Securities under Rule 144 even if the other applicable requirements of Rule 144 have been satisfied. The Investor understands
and acknowledges that, in the event the applicable requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration will be required for any disposition of the Securities. The Investor understands
that, although Rule 144 is not exclusive, the Securities and Exchange Commission has expressed its opinion that persons proposing to sell restricted securities received in a private offering other than in a registered offering or pursuant to
Rule 144 will have a substantial burden of proof in establishing that an exemption from registration is available for those offers or sales and that those persons and the brokers who participate in the transactions do so at their own risk. 

9. No Public Market. The Holder understands and acknowledges that no public market now exists for any of the securities issued by the
Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities. 
 10.
Brokers and Finders. The Investor has not engaged any brokers, finders or agents in connection with the Securities, and the Company has not incurred nor will incur, directly or indirectly, as a result of any action taken by the Investor, any
liability for brokerage or finders’ fees or agents’ commissions or any similar charges in connection with the Securities. 
 11.
Legal Counsel. The Investor has had the opportunity to review the Warrant, the exhibits and schedules attached thereto and the transactions contemplated by the Warrant with its own legal counsel. The Investor is not relying on any statements
or representations of the Company or its agents for legal advice with respect to this investment or the transactions contemplated by the Warrant. 

12. Tax Advisors. The Investor has reviewed with its own tax advisors the U.S. federal, state and local and non-U.S. tax consequences
of this investment and the transactions contemplated by the 

  
 A-1-2 

 
Warrant. With respect to such matters, the Investor relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The Investor
understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment or the transactions contemplated by the Warrant. 

13. Market Stand-off. The Investor agrees that the Investor shall not sell or otherwise transfer, make any short sale of, grant any
option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, of any common stock (or other securities) of the Company held by the Investor (other than those included in the registration)
during the one hundred eighty (180) day period following the effective date of the registration statement for the Company’s initial public offering filed under the Securities Act (or such other period as may be requested by the Company or
an underwriter to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD
Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto). The obligations described in this section shall not apply to a registration relating solely to employee benefit plans on Form S-l or Form S-8 or
similar forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions and may stamp each
certificate with a legend with respect to the shares of common stock (or other securities) subject to the foregoing restriction until the end of such one hundred eighty (180) day (or other) period. The Investor agrees to execute a market
stand-off agreement with the relevant underwriters in customary form consistent with the provisions of this section. 
 (signature page
follows) 

  
 A-1-3 

 The Investor is signing this Investment Representation Statement and Market Stand-Off Agreement
on the date first written above. 
  

	
	INVESTOR
	
	  

	(Print name of the investor)
	
	  

	(Signature)
	
	  

	(Name and title of signatory, if applicable)
	
	  

	(Street address)
	
	  

	(City, state and ZIP)

  
 A-1-4 

 EXHIBIT B 

ASSIGNMENT FORM 
  

					
	ASSIGNOR:		«WARRANT_HOLDER»
		
	COMPANY:		BIOCARDIA, INC.
		
	WARRANT:		THE WARRANT TO PURCHASE SHARES OF SERIES F PREFERRED STOCK ISSUED ON «DATE» (THE “WARRANT”)
			
	DATE:		  
		

  

	(1)	Assignment. The undersigned registered holder of the Warrant (“Assignor”) assigns and transfers to the assignee named below (“Assignee”) all of the rights of
Assignor under the Warrant, with respect to the number of shares set forth below: 

  

			
	Name of Assignee:		  

		
	Address of Assignee:		  

		
			  

		
	Number of Shares Assigned:		  

 and does irrevocably constitute and appoint
                     as attorney to make such transfer on the books of BioCardia, Inc., maintained for the purpose, with full power of substitution
in the premises. 
  

	(2)	Obligations of Assignee. Assignee agrees to take and hold the Warrant and any shares of stock to be issued upon exercise of the rights thereunder (and any shares issuable upon conversion thereof) (the
“Securities”) subject to, and to be bound by, the terms and conditions set forth in the Warrant to the same extent as if Assignee were the original holder thereof. 

 

	(3)	Investment Intent. Assignee represents and warrants that the Securities are being acquired for investment for its own account, not as a nominee or agent, and not with a view to, or for resale in connection with,
the distribution thereof, and that Assignee has no present intention of selling, granting any participation in, or otherwise distributing the shares, nor does it have any contract, undertaking, agreement or arrangement for the same, and all
representations and warranties set forth in Section 11 of the Warrant are true and correct as to Assignee as of the date hereof. 

  

	(4)	Investment Representation Statement and Market Stand-Off Agreement. Assignee has executed, and delivers herewith, an Investment Representation Statement and Market Stand-Off Agreement in a form substantially
similar to the form attached to the Warrant as Exhibit A-1. 

  
 - 1 - 

 Assignor and Assignee are signing this Assignment Form on the date first set forth above. 

 

					
	ASSIGNOR				ASSIGNEE
			
	  
				  

	(Print name of Assignor)				(Print name of Assignee)
			
	  
				  

	(Signature of Assignor)				(Signature of Assignee)
			
	  
				  

	(Print name of signatory, if applicable)				(Print name of signatory, if applicable)
			
	  
				  

	(Print title of signatory, if applicable)				(Print title of signatory, if applicable)
			
	Address:				Address:
			
	  
				  

			
	  
				  

  
 - 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]